Troy O. Harasym - Concepedia

Author

Troy O. Harasym

Also Known As

Harasym, Troy O., T. Harasym, T. O. Harasym, T.O. Harasym, Troy O. Harasym, Troy Harasym, Troy O Harasym, Troy O. Harasym

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Celator Pharmaceuticals (Canada)BC Cancer Agency University of British Columbia Inimex Pharmaceuticals (Canada)Arbutus Biopharma (Canada)

About

Troy O. Harasym is an author at Celator Pharmaceuticals (Canada) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	925
2	Biochemistry	5	5	623
3	Natural Sciences	3	3	559
4	Biomolecular Engineering	2	2	489
5	Engineering	1	1	42

Troy O. Harasym

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures Sean C. Semple, Sandra K. Klimuk, Troy O. Harasym, Biochimica et Biophysica Acta (BBA) - Biomembranes Lipid PreparationProteinlipid InteractionBiochemistryNatural SciencesOligonucleotide	2001	447
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy Paul Tardi, Sharon A. Johnstone, Natashia Harasym, Leukemia Research Daunorubicin RatiosPharmacologyVivo MaintenancePharmacotherapyDrug Development	2008	349
Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice Lawrence D. Mayer, Troy O. Harasym, Paul Tardi, Molecular Cancer Therapeutics	2006	324
Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid Sean C. Semple, Troy O. Harasym, Kathy A. Clow, Journal of Pharmacology and Experimental Therapeutics	2005	209
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts Wah-Seng Lim, Paul Tardi, Nancy Dos Santos, Leukemia Research Hematological MalignancyLeukemia-selective UptakeMedicineHematologyBone Marrow Xenografts	2010	155
Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1 Jang‐June Park, Emily P. Thi, Victor H. Carpio, Nature Communications	2021	130
Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates Steven M. Ansell, Sharon A. Johnstone, Paul Tardi, Journal of Medicinal Chemistry	2008	124
Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations <i>in vitro</i> and <i>in vivo</i> Paul Tardi, Nancy Dos Santos, Troy O. Harasym, Molecular Cancer Therapeutics	2009	118
<b> <i>In Vitro</i> </b> and <b> <i>in Vivo</i> </b> Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading Sheela A. Abraham, Cheryl McKenzie, Dana Masin, Clinical Cancer Research	2004	106
Increased Preclinical Efficacy of Irinotecan and Floxuridine Coencapsulated Inside Liposomes Is Associated With Tumor Delivery of Synergistic Drug Ratios Troy O. Harasym, Paul Tardi, Natashia Harasym, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics NanotherapeuticsPharmacotherapyTumor BiologyOncologyPreclinical Efficacy	2006	83

Page 1